Low-intensity extracorporeal shockwave therapy for erectile dysfunction. Issue 3 (3rd July 2021)

• Record Type: Journal Article
• Authors: Canguven, Onder; Khalafalla, Kareim; Al Ansari, Abdulla
• Is Part Of: Arab journal of urology. Volume 19:Issue 3(2021)
• Page Start: 340
• Page End: 345
• Publication Date: 2021-07-03
• Subjects: Low-intensity extracorporeal shockwave therapy -- erectile dysfunction -- erection -- male; Urology -- Periodicals; Urology; Urologic Diseases; Urologic Surgical Procedures; Urogenital Neoplasms; Arabia; Periodicals; 616.6
• DOI: 10.1080/2090598X.2021.1948158
• Languages: English
• ISSNs: 2090-598X

Abstract

ABSTRACT: Objectives : To review the current evidence of clinical effectiveness of low-intensity extracorporeal shockwave therapy (LI-ESWT) treatment for erectile dysfunction (ED). Methods: A selective database search using Medical Subject Headings (MeSH) terms 'low intensity extracorporeal shock wave therapy' and 'erectile dysfunction' was conducted in accordance with the Preferred Reporting Items for Systemic Reviews and Meta Analyses (PRISMA) guidelines to review the effectiveness of LI-ESWT for ED. We performed a systematic search of publications using the PubMed and Web of Science databases (January 2010–December 2020) for prospective randomised clinical trials (RCTs). The success rate of LI-ESWT associated with ED were recorded and analysed. Results: A total of 106 articles were reviewed after searching for the keywords. Overall, 11 RCTs were included in this systematic review. A total of 920 male patients were treated in 11 RCTs. The patients' ages ranged from 18 to 80 years and they had ≥3 months of ED symptoms. Vasculogenic and neurogenic causes were addressed in 81% and 19% of patients, respectively. Of the 920 patients, 348 patients had a statistically significant improvement in their erectile function after LI-ESWT; however, 572 did not have a statistically significant improvement. Conclusions: The present review found that LI-ESWT has a role in ED treatment in laboratory studies, but its role in human clinical trials is still controversial. Further good quality studies need to be conducted to properly assess its true potential in ED treatment.